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Abstract
West Nile virus, first identified within the United States in 1999, has since spread across the continental states and infected
birds, humans and domestic animals, resulting in numerous deaths. Previous studies in mice identified the Oas1b gene, a
member of the OAS/RNASEL innate immune system, as a determining factor for resistance toWest Nile virus (WNV) infection. A
recent case-control association study described mutations of human OAS1 associated with clinical susceptibility to WNV
infection. Similar studies in horses, a particularly susceptible species, have been lacking, in part, because of the difficulty in
collecting populations sufficiently homogenous in their infection and disease states. The equine OAS gene cluster most closely
resembles the human cluster, with single copies of OAS1, OAS3 and OAS2 in the same orientation. With naturally occurring
susceptible and resistant sub-populations to lethal West Nile encephalitis, we undertook a case-control association study to
investigate whether, similar to humans (OAS1) and mice (Oas1b), equine OAS1 plays a role in resistance to severe WNV
infection. We identified naturally occurring single nucleotide mutations in equine (Equus caballus) OAS1 and RNASEL genes
and, using Fisher’s Exact test, we provide evidence that mutations in equine OAS1 contribute to host susceptibility. Virtually all
of the associated OAS1 polymorphisms were located within the interferon-inducible promoter, suggesting that differences in
OAS1 gene expression may determine the host’s ability to resist clinical manifestations associated with WNV infection.
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Introduction
The innate immune response confers host resistance by the
recognition and limitation of viral infection and replication.
Previous investigations of the innate immune response to West
Nile virus (WNV) infection were conducted using inbred strains of
naturally susceptible and resistant mice [1,2]. Using a positional
cloning strategy, the Flavivirus resistance (Flv) gene was identified
as 29,59-oligoadenylate synthetase 1b (Oas1b). The interferon
(IFN)-induced OAS genes encode dsRNA-activated proteins which
catalyze the synthesis of 29-59-linked oligoadenylate molecules (2-
5A) from ATP [3–5]. The only known function of 2-5A molecules
is to activate Ribonuclease L (RNASEL) for the degradation of
cellular and viral RNA [3,6–8].
OAS proteins are encoded by multiple genes, collectively
referred to as the OAS gene cluster. Gene clusters vary between
species in both number of genes and splice variants. The rodent
Oas1 locus expanded to a family of 12 genes, while both the canine
and bovine clusters contain duplications of OASL and OAS1 genes,
respectively [9,10]. However, both equine and human OAS
clusters contain single copies of each gene in the same orientation,
OAS1-OAS3-OAS2 and a single OASL gene [9,11].
Previously, Yakub et al. found a SNP in human OASL associated
with WNV susceptibility; however, this association was not
replicated in a larger case-control study [12,13]. Case-control
association studies are best implemented using homogenous
populations, which reduces systematic bias from sample selection
and minimizes the potential for false positive associations inherent
within the population structures [14]. Lim et al. recently identified
human OAS1 SNP rs10774671 in an association study of
symptomatic and asymptomatic seroconverters [12]. In this study,
case samples were compared to a control population of WNV
false-positives. This SNP is located in an intron 5 splice site
resulting in differential splicing and a protein product with
diminished enzymatic activity. Taken together, data from both
human and mouse studies support our investigation of equine
candidate genes OAS1 and RNASEL.
Susceptibility to severe West Nile encephalitis among mammals
is naturally variable [15]. Experimental infections in sheep [16],
calves [17], pigs [18], and dogs [19] have shown these domestic
species to be poor hosts for, or develop only mild clinical
symptoms from WNV infection, thereby limiting their usefulness
for genetic susceptibility/resistance studies. Horses however, are
particularly susceptible to severe WNV infection, suffering clinical
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symptoms including fever, ataxia, paralysis and death [20].
Because many horses infected with WNV remain asymptomatic
or present only mild symptoms, horses are an excellent model
organism to test for genetic susceptibility using strictly phenotyped
case and control populations. This advantage is complicated,
however, by the inaccessibility of well-characterized case and
control samples for retrospective study.
As mentioned above, one advantage of a horse model is the
ability to monitor both infection in control samples and WNV-
induced encephalitis in case samples. In this report, we describe a
two-stage association study of naturally occurring equine OAS1
and RNASEL mutations to investigate a potential role of these
genes in the equine innate immune response to WNV infection.
Because of the limited retrospective accessibility to adequately
phenotyped samples with known pre- and post-infection status,
our population sizes did not allow matching of case and control
samples by breed. Although no breed-specific difference in
susceptibility has been reported, our analysis showed the
associations identified from these populations were not artifacts
of the two most frequent breeds in our case population. Because
most significantly associated SNPs were present in the OAS1
promoter region, we conducted reporter assays to measure the
response of equine OAS1 promoter constructs to interferon
stimulation by transient transfection using human transformed
cell lines.
Results
Defining case and control population samples
The control population consisted of 16 healthy, previously
uninfected (naı¨ve) horses of multiple breeds, including Thorough-
bred (13), Quarterhorse (1), Paso Fino (1) and a single mixed breed
horse. These unvaccinated horses were naturally infected with
WNV by mosquito transmission during the height of the initial
Florida epidemic of 2001, when only the NY99 strain was present.
Control horses were monitored daily, yet failed to exhibit clinical
symptoms. These healthy individuals tested positive for WNV
infection and were therefore classified as subclinical seroconver-
ters. An important characteristic of our case-control study, all
horses included in the control population had an equal
opportunity of being classified in the case population, had they
displayed clinical symptoms post-infection.
Horses included in the case population were previously
unvaccinated and naturally infected through mosquito transmis-
sion. Multiple breeds were present among the 44 case horses, the
most common of which included Thoroughbred (12) and
Quarterhorse (10), with 2 horses of unknown breed. All case
horses developed clinical encephalitic symptoms diagnosed with
veterinary treatment, ultimately requiring humane euthanasia.
Veterinary examination noted multiple symptoms, the most
common including forelimb and/or hindlimb ataxia. Diagnostic
tests confirmed WNV infection by enzyme-linked immunosorbent
assay (ELISA) or polymerase chain reaction (PCR).
An important characteristic shared by both the case and control
populations, horses were unvaccinated prior to infection and all
horses were infected by natural mosquito transmission during the
early stages of the initial U.S. epidemic, between 2001 and 2002.
SNP genotyping and association analysis
Previously, we sequenced the coding regions of equine OAS1
and RNASEL as well as the OAS1 promoter from a random
population and identified SNPs for case-control association [21].
In this study, we genotyped 49 equine OAS1 and RNASEL
mutations in 16 control and 44 case samples. Genotype data were
analyzed to identify statistically significant allelic (262) and
genotypic (263) associations to WNV phenotype using the
conservative Fisher’s Exact test. Fifteen SNPs in OAS1 and three
SNPs in exon 2 of RNASEL were significantly associated (262,
p,0.05) with WNV susceptibility (Table 1). The statistical
associations of OAS1 mutations were not uniformly scattered
throughout the entire gene but were concentrated in the upstream
regulatory region, with twelve of the significantly associated
mutations located in the OAS1 promoter and 59 untranslated
region (UTR). Using the highly conservative Bonferonni threshold
for statistical significance, only mutations of the OAS1 promoter (6
of 49) were associated (262, p,0.001) with WNV susceptibility.
Next, we used odds ratios (OR) to measure the strength of the SNP
associations (Table 1). All significantly associated mutations had
ORs greater than 1.0. Among significantly associated mutations of
the OAS1 regulatory region, all but one had 95% OR confidence
intervals greater than 1.0.
Deviation from Hardy-Weinberg Equilibrium (HWE) can be a
useful tool to indicate errors in genotyping or population
stratification [22]. To investigate this possibility, exact tests were
used to determine if genotype frequencies in the control
population deviated from HWE. Two SNPs (ss104806941 and
ss104806963) failed the HWE test (Table 2), but neither SNP was
associated with WNV susceptibility. Tests of HWE may also be
informative for association studies when measured in the case
population. Within our case population, many SNPs deviated
significantly (p,0.05) from HWE (Table 2), and SNPs with the
greatest deviation (lowest p-value) were in the OAS1 promoter.
Exact tests for HWE in the control and case populations supported
the significant associations of 6 of the 10 OAS1 promoter
mutations.
To investigate potential false-positive SNP associations from
over-represented case breeds, Quarterhorse (n = 10) and Thor-
oughbred (n = 12) case samples, together representing 50% of the
population, were independently compared to the control popula-
tion. Seven of the 8 mutations statistically significant in both case-
breed analyses were in the equine OAS1 promoter (Table 3). Using
the two most represented breeds of the case population, these
analyses allow us to conclude that the SNP associations to WNV
susceptibility are not artifacts attributable to breed specific allele
frequencies in the major breeds of our case study population.
Haplotype assembly and association analysis
Fifteen SNPs genotyped in the promoter, 59UTR and exon 1 of
equine OAS1 were used to infer haplotypes among case and
control samples. From the assembled best reconstruction, we
identified six tagSNPs (ss104806918, ss104806922, ss104806924,
ss104806926, ss104806927 and ss104806931) with calculated
mean percentage diversity explained (PDE) of 99.23% [23]. These
tagSNPs, all associated with WNV susceptibility, were used to re-
construct haplotypes and conduct case-control comparisons.
Haplotype frequencies were significantly different (p,0.01)
between case and control populations. A single common haplotype
(GACCGT) was assembled in 65.6% and 23.3% of control and
case sample chromosomes, respectively. Fisher’s Exact test showed
deviations from this haplotype were significantly associated
(p = 4.953 e-6) with susceptibility to severe WNV disease, with
an odds ratio of 7.58 (95% CI = 2.88: 21.18). Five of the six alleles
in this haplotype were found to be protective in our study,
consistent with the increased haplotype frequency in the control
population. This haplotype data supports the OAS1 promoter SNP
associations to WNV susceptibility.
Equine RNASEL haplotypes were inferred from 42 horses
genotyped at $75% of all RNASEL SNPs in order to minimize the
OAS1 and WNV in Horses
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Table 1. Statistical association of single nucleotide polymorphisms to West Nile encephalitis.
SNP ID Gene Region Allele
Case Allele
Frequency
Control Allele
Frequency
Fisher
Exact 263
Fisher
Exact 262
Odds
Ratio
Odds Ratio
95% CI
ss104806917 OAS1 Promoter C 0.60 0.20 0.0001 0.0002 5.844 2.043; 19.437
ss104806918 OAS1 Promoter T 0.57 0.20 3.118e-5 0.0006 5.256 1.846; 17.405
ss104806919 OAS1 Promoter G 0.40 0.19 0.3181 0.0305 2.921 1.030; 9.621
ss104806920 OAS1 Promoter T 0.54 0.19 9.465e-6 0.0008 4.933 1.750; 16.210
ss104806921 OAS1 Promoter C 0.51 0.19 0.0001 0.0016 4.488 1.592; 14.720
ss104806922 OAS1 Promoter T 0.33 0.13 0.0072 0.0351 3.468 1.060; 14.934
ss104806923 OAS1 Promoter T 0.53 0.19 2.676e-5 0.0008 4.918 1.750; 16.123
ss104806924 OAS1 Promoter T 0.55 0.19 0.0003 0.0007 5.151 1.832; 16.900
ss104806925 OAS1 Promoter G 0.98 0.88 0.0494 0.0546 5.470 0.738; 63.646
ss104806926 OAS1 Promoter T 0.66 0.19 1.227e-5 6.95e-6 8.189 2.869; 27.277
ss104806927 OAS1 Promoter G 0.97 0.84 0.0563 0.0232 6.709 0.023; 0.012
ss104806928 OAS1 59UTR G 0.54 0.17 0.0356 0.0017 5.773 1.772; 22.631
ss104806929 OAS1 59UTR A 0.50 0.19 0.0705 0.0082 4.252 1.372; 15.087
ss104806930 OAS1 Exon 1 G 0.10 0.06 1.0000 0.6962 1.733 0.262; 19.333
ss104806931 OAS1 Exon 1 C 0.44 0.19 0.1304 0.0196 3.418 1.132; 11.840
ss104806932 OAS1 Intron 1 T 0.22 0.28 0.7197 0.4745 0.721 0.261; 2.090
ss104806933 OAS1 Exon 2 T 0.31 0.28 0.4466 0.8213 1.151 0.428; 3.285
ss104806934 OAS1 Exon 2 T 0.84 0.72 0.1275 0.1894 2.003 0.663; 5.874
ss104806935 OAS1 Exon 2 A 0.83 0.72 0.1487 0.1949 1.944 0.642; 5.707
ss104806936 OAS1 Exon 2 G 0.84 0.72 0.1275 0.1894 2.003 0.663; 5.874
ss104806937 OAS1 Exon 2 G 0.83 0.72 0.1734 0.2996 1.834 0.613; 5.295
ss104806938 OAS1 Exon 4 C 0.73 0.47 0.0456 0.0144 3.042 1.196; 7.893
ss104806939 OAS1 Intron 4 C 0.63 0.47 0.2948 0.1746 1.952 0.733; 5.296
ss104806940 OAS1 Intron 4 G 0.73 0.43 0.0849 0.0098 3.490 1.244; 10.189
ss104806941 OAS1 Intron 4 G 0.51 0.33 0.4243 0.1262 2.102 0.802; 5.803
ss104806942 OAS1 Exon 5 G 0.41 0.17 0.2279 0.0538 3.432 0.960; 14.328
ss104806943 OAS1 Intron 5 T 0.54 0.43 0.3564 0.3824 1.554 0.603; 4.082
ss104806944 OAS1 Intron 5 G 0.51 0.43 0.6787 0.5150 1.382 0.537; 3.626
ss104806945 OAS1 Exon 6 T 0.38 0.27 0.3278 0.3480 1.641 0.572; 5.062
ss104806946 OAS1 39UTR T 0.38 0.53 0.1535 0.2407 0.529 0.188; 1.462
ss104806947 RNASEL Exon 2 C 0.57 0.31 0.1809 0.0351 2.889 1.013; 8.694
ss104806948 RNASEL Exon 2 A 0.88 0.69 0.0688 0.0464 3.263 0.977; 11.549
ss104806949 RNASEL Exon 2 T 0.35 0.38 0.9186 0.8232 0.898 0.338; 2.434
ss104806950 RNASEL Exon 2 C 0.85 0.69 0.1197 0.1030 2.547 0.806; 8.212
ss104806951 RNASEL Exon 2 G 0.30 0.28 1.0000 1.0000 1.094 0.389; 3.234
ss104806952 RNASEL Exon 2 C 0.26 0.38 0.5506 0.2470 0.583 0.212; 1.616
ss104806953 RNASEL Exon 2 C 0.78 0.72 0.1766 0.6119 1.350 0.439; 4.023
ss104806954 RNASEL Exon 2 C 0.26 0.22 0.8220 0.8068 1.277 0.440; 4.079
ss104806955 RNASEL Exon 2 G 0.61 0.44 0.2420 0.1345 2.006 0.800; 5.135
ss104806956 RNASEL Exon 2 G 0.81 0.86 0.2621 0.7673 0.697 0.148; 2.625
ss104806957 RNASEL Exon 2 G 0.67 0.82 0.3144 0.1448 0.438 0.115; 1.401
ss104806958 RNASEL Exon 2 G 0.38 0.25 0.4311 0.3308 1.821 0.615; 5.933
ss104806959 RNASEL Exon 2 A 0.55 0.21 0.0267 0.0035 4.465 1.533; 15.032
ss104806960 RNASEL 39UTR G 0.87 0.86 0.8300 1.0000 1.110 0.208; 5.240
ss104806961 RNASEL 39UTR A 0.89 0.79 0.4864 0.3070 2.030 0.413; 10.025
ss104806962 RNASEL 39UTR T 0.83 0.75 0.7527 0.3765 1.657 0.445; 5.643
ss104806963 RNASEL 39UTR C 0.41 0.25 0.2983 0.2190 2.061 0.670; 7.195
ss104806964 RNASEL 39UTR T 0.17 0.12 1.0000 0.7410 1.596 0.351; 10.058
ss104806965 RNASEL 39UTR T 0.67 0.73 0.7255 0.6159 0.740 0.221; 2.281
doi:10.1371/journal.pone.0010537.t001
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effect of unknown genotypes. Six tagSNPs (ss104806949,
ss104806954, ss104806955, ss104806958, ss104806959 and
ss104806965) were identified with total mean PDE of 99.33%.
Haplotypes were re-constructed using these tagSNPs from the
same 42 samples and, in contrast to OAS1, haplotype frequencies
were not found to differ significantly between case and control
populations (p = 0.53).
Interferon stimulation of equine OAS1 promoter
Since many of the SNPs associated with WNV susceptibility
were present in the OAS1 promoter and because human OAS1 is
induced by IFN-stimulated regulatory factors acting through an
IFN-stimulated response element (ISRE) proximal to the tran-
scription start site (TSS, Figure S1) [24], we conducted
preliminary transient transfection experiments to determine if
these mutations could alter IFN induction of the equine OAS1
promoter.
Functional assays of the OAS1 promoter by transient transfec-
tion should be conducted in equine cell lines derived from tissues
involved in the early development of post-infection WNV disease,
but such cell lines are currently unavailable. We therefore
substituted two cell lines, 2fTGH and HepG2, that have been
extensively used in studies of IFN and/or OAS [25–29].
Haplotypes of the proximal promoter of equine OAS1 were
cloned upstream of the luciferase reporter coding region (Figure 1).
Proximal promoter constructs were generated as deletions of the
full-length clones mentioned below. These deletion constructs
(EcOAS1D59_A-Luc and EcOAS1D59_B-Luc) lack the polymor-
phic microsatellite and sequence further upstream. These
proximal promoter constructs were used in transient transfection
assays of 2fTGH cells (a derivative of HT1080 cells) treated with
104 antiviral units (AVU) of interferon (IFN). Luciferase reporter
activity 24 h after stimulation was 7- to 8-fold higher than basal
levels (data not shown). Therefore, the proximal region from the
TSS to the microsatellite (,518 bp) was found to be necessary and
sufficient for equine OAS1 promoter responsiveness to IFN. This is
the first direct observation of equine OAS1 promoter IFN
responsiveness.
Additional promoter sequence containing the polymorphic
microsatellite and upstream sequence was cloned upstream of
the luciferase reporter coding region (Figure 1). Full-length
promoter clone EcOAS1_A-Luc contains the alleles of the
common haplotype previously mentioned (GACCG) while
EcOAS1_B-Luc and EcOAS1_C-Luc contain the TATTG and
TTTTG haplotypes, respectively. Additionally, each full-length
clone contains a previously identified polymorphic microsatellite
with repeat lengths of 9 (A), 16 (B) and 19 (C) [21].
Full-length constructs were transfected into 2fTGH cells and
treated with different doses (102 to 104 AVU/mL) of IFN for
24 h. IFN stimulated activity of each OAS construct in a dose-
dependent manner (Figure 2). The variation between experi-
ments was greater for the EcOAS1_B-Luc construct; however,
the average fold induction across three replicates for the
EcOAS1_A-Luc construct was ,2- and ,4-fold greater than
Table 2. Exact test of HWE among equine OAS1 and RNASEL
SNPs.
SNP ID Gene Region
Control HWE
p-value
Case HWE
p-value
ss104806917 OAS1 Promoter 0.4605 0.1179
ss104806918 OAS1 Promoter 0.4605 0.0048
ss104806919 OAS1 Promoter 0.4344 0.0003
ss104806920 OAS1 Promoter 0.4344 0.0004
ss104806921 OAS1 Promoter 0.4344 0.0047
ss104806922 OAS1 Promoter 1.000 0.0012
ss104806923 OAS1 Promoter 0.4344 0.0021
ss104806924 OAS1 Promoter 0.4344 0.1265
ss104806925 OAS1 Promoter 1.000 3.2785 e-9
ss104806926 OAS1 Promoter 0.4344 0.3088
ss104806927 OAS1 Promoter 0.3059 1.0000
ss104806928 OAS1 59UTR 0.3257 0.0165
ss104806929 OAS1 59UTR 0.4344 0.0914
ss104806930 OAS1 Exon 1 1.0000 0.2057
ss104806931 OAS1 Exon 1 0.4344 0.0500
ss104806932 OAS1 Intron 1 1.0000 0.3651
ss104806933 OAS1 Exon 2 1.0000 0.0652
ss104806934 OAS1 Exon 2 1.0000 0.0449
ss104806935 OAS1 Exon 2 1.0000 0.0483
ss104806936 OAS1 Exon 2 1.0000 0.0449
ss104806937 OAS1 Exon 2 1.0000 0.0727
ss104806938 OAS1 Exon 4 0.6376 0.0986
ss104806939 OAS1 Intron 4 0.6376 0.0378
ss104806940 OAS1 Intron 4 0.2939 0.0440
ss104806941 OAS1 Intron 4 0.0101 3.1126 e-6
ss104806942 OAS1 Exon 5 0.3257 0.0452
ss104806943 OAS1 Intron 5 0.2939 1.0000
ss104806944 OAS1 Intron 5 0.2939 0.5044
ss104806945 OAS1 Exon 6 1.0000 0.0161
ss104806946 OAS1 39UTR 0.6035 0.3916
ss104806947 RNASEL Exon 2 0.1068 0.3771
ss104806948 RNASEL Exon 2 0.5914 1.0000
ss104806949 RNASEL Exon 2 0.5914 0.1016
ss104806950 RNASEL Exon 2 0.5914 1.0000
ss104806951 RNASEL Exon 2 0.5301 0.0730
ss104806952 RNASEL Exon 2 1.0000 0.3682
ss104806953 RNASEL Exon 2 1.0000 0.0134
ss104806954 RNASEL Exon 2 0.1081 0.0003
ss104806955 RNASEL Exon 2 0.3477 0.0015
ss104806956 RNASEL Exon 2 1.0000 0.0042
ss104806957 RNASEL Exon 2 1.0000 0.1101
ss104806958 RNASEL Exon 2 1.0000 0.0435
ss104806959 RNASEL Exon 2 0.0647 0.0261
ss104806960 RNASEL 39UTR 0.2178 0.0229
ss104806961 RNASEL 39UTR 0.4037 1.0000
ss104806962 RNASEL 39UTR 0.0899 0.0352
ss104806963 RNASEL 39UTR 0.0016 0.0001
ss104806964 RNASEL 39UTR 1.0000 1.0000
SNP ID Gene Region
Control HWE
p-value
Case HWE
p-value
ss104806965 RNASEL 39UTR 0.1652 0.0007
doi:10.1371/journal.pone.0010537.t002
Table 2. Cont.
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Table 3. Quarterhorse and Thoroughbred breed case-control allelic Fisher’s Exact analysis.
SNP ID Gene Region Allele
Case
Allele
Freq.
Control
Allele Freq.
Case
Quarterhorse
Allele Freq.
Case Quarter-
horse Fisher
Exact 262
Case
Thoroughbred
Allele Freq.
Case
Thoroughbred
Fisher Exact 262
ss104806917 OAS1 Promoter C 0.60 0.20 0.65 0.0025 0.64 0.0033
ss104806918 OAS1 Promoter T 0.57 0.20 0.60 0.0065 0.63 0.0021
ss104806919 OAS1 Promoter G 0.40 0.19 0.45 0.0607 0.29 0.5237
ss104806920 OAS1 Promoter T 0.54 0.19 0.50 0.0297 0.63 0.0018
ss104806921 OAS1 Promoter C 0.51 0.19 0.55 0.0137 0.50 0.0205
ss104806922 OAS1 Promoter T 0.33 0.13 0.30 0.1562 0.42 0.0268
ss104806923 OAS1 Promoter T 0.53 0.19 0.50 0.0297 0.54 0.0096
ss104806924 OAS1 Promoter T 0.55 0.19 0.50 0.0297 0.54 0.0096
ss104806925 OAS1 Promoter G 0.98 0.88 1.00 0.1507 1.00 0.1368
ss104806926 OAS1 Promoter T 0.66 0.19 0.65 0.0012 0.73 0.0002
ss104806927 OAS1 Promoter G 0.97 0.84 1.00 0.1542 1.00 0.0720
ss104806928 OAS1 59UTR G 0.54 0.17 0.50 0.0852 0.50 0.0852
ss104806929 OAS1 59UTR A 0.50 0.19 0.50 0.0944 0.63 0.3476
ss104806930 OAS1 Exon 1 G 0.10 0.06 0.10 1.0000 0.00 1.0000
ss104806931 OAS1 Exon 1 C 0.44 0.19 0.75 0.7118 0.56 0.0900
ss104806932 OAS1 Intron 1 T 0.22 0.28 0.17 0.4973 0.21 0.7561
ss104806933 OAS1 Exon 2 T 0.31 0.28 0.39 0.5322 0.27 1.0000
ss104806934 OAS1 Exon 2 T 0.84 0.72 0.72 1.0000 0.92 0.0926
ss104806935 OAS1 Exon 2 A 0.83 0.72 0.33 0.7544 0.05 0.0358
ss104806936 OAS1 Exon 2 G 0.84 0.72 0.67 0.7544 0.96 0.0329
ss104806937 OAS1 Exon 2 G 0.83 0.72 0.67 0.7544 0.96 0.0329
ss104806938 OAS1 Exon 4 C 0.73 0.47 0.15 0.0083 0.17 0.0062
ss104806939 OAS1 Intron 4 C 0.63 0.47 0.42 0.7360 0.33 0.3182
ss104806940 OAS1 Intron 4 G 0.73 0.43 0.57 0.5206 0.83 0.0372
ss104806941 OAS1 Intron 4 G 0.51 0.33 0.63 0.0701 0.35 1.0000
ss104806942 OAS1 Exon 5 G 0.41 0.17 0.25 0.6236 0.17 1.0000
ss104806943 OAS1 Intron 5 T 0.54 0.43 0.56 0.5524 0.63 0.3534
ss104806944 OAS1 Intron 5 G 0.51 0.43 0.50 0.7676 0.63 0.3534
ss104806945 OAS1 Exon 6 T 0.38 0.27 0.42 0.4635 0.28 1.0000
ss104806946 OAS1 39UTR T 0.38 0.53 0.29 0.1948 0.36 0.3419
ss104806947 RNASEL Exon 2 C 0.57 0.31 0.50 0.4162 0.58 0.1641
ss104806948 RNASEL Exon 2 A 0.88 0.69 0.21 0.7241 0.00 0.0085
ss104806949 RNASEL Exon 2 T 0.35 0.38 0.64 0.1088 0.33 1.0000
ss104806950 RNASEL Exon 2 C 0.85 0.69 0.25 0.7460 0.00 0.0196
ss104806951 RNASEL Exon 2 G 0.30 0.28 0.63 0.0306 0.25 1.0000
ss104806952 RNASEL Exon 2 C 0.26 0.38 0.38 1.0000 0.17 0.1990
ss104806953 RNASEL Exon 2 C 0.78 0.72 1.00 0.0406 0.71 1.0000
ss104806954 RNASEL Exon 2 C 0.26 0.22 0.50 0.0963 0.27 0.7500
ss104806955 RNASEL Exon 2 G 0.61 0.44 0.31 0.5352 0.63 0.1761
ss104806956 RNASEL Exon 2 G 0.81 0.86 0.94 0.6342 0.67 0.1569
ss104806957 RNASEL Exon 2 G 0.67 0.82 0.94 0.3920 0.61 0.1703
ss104806958 RNASEL Exon 2 G 0.38 0.25 0.21 1.0000 0.36 0.4913
ss104806959 RNASEL Exon 2 A 0.55 0.21 0.40 0.2061 0.45 0.1170
ss104806960 RNASEL 39UTR G 0.87 0.86 1.00 0.2969 0.58 0.0968
ss104806961 RNASEL 39UTR A 0.89 0.79 0.17 1.0000 0.10 0.6445
ss104806962 RNASEL 39UTR T 0.83 0.75 0.70 0.7456 0.90 0.2591
ss104806963 RNASEL 39UTR C 0.41 0.25 0.89 0.4307 0.44 0.0590
ss104806964 RNASEL 39UTR T 0.17 0.12 0.08 1.0000 0.33 0.1284
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the EcOAS1_C-Luc construct when cells were treated with
103 AVU and 104 AVU, respectively. The greatest differences
in fold induction between clones occurred when cells were
treated with 10,000 AVU IFN (ANOVA, p = 0.026); however,
little difference was seen between constructs when cells were
treated with only 100 AVU for 24 h.
Because the difference in fold induction between constructs may
be an artifact of the high IFN concentration used and the long
exposure time, full-length constructs were transfected into HepG2
liver cells, which have been used in previous studies of OAS
expression, and treated for 6 h or 24 h [29]. Similar to the 2fTGH
experiment, equine OAS1 promoter induction in HepG2 cells
showed a dose-response to IFN at both 6 h and 24 h (Figure 3).
Averaged across 4 replicates, the fold induction was similar
between clones both at 6 h and 24 h when cells were treated with
103 AVU IFN (ANOVA, p.0.05). However, when HepG2 cells
were treated with 100 AVU IFN for 6 h, construct EcOAS1_
A-Luc was induced at higher fold levels than the other clones
(ANOVA, p,0.001). OAS is part of the immediate early response
of cells to viral infection, and previous studies of OAS promoter
function have included lower IFN doses and shorter exposure
periods to mimic early times after infection [28]. These
preliminary data suggest a similar model, and when considered
with the promoter SNP and haplotype associations, suggest
promoter mutations affecting equine OAS1 expression may
contribute, in part, to susceptibility to severe WNV disease.
Discussion
The first evidence for an involvement of the OAS gene family in
innate resistance to West Nile virus was provided using a mouse
model [1,2]. However, the rodent OAS cluster contains numerous
copies of the Oas1 gene and the comprehensive cluster structure is
largely different from the human gene cluster. Another study
recently provided evidence of a role for human OAS1 in innate
resistance to WNV infection [12]. With our ability to closely
monitor response to West Nile virus infection, we used the horse as
a model to identify a potential association of the equine OAS1 gene
to WNV resistance or susceptibility through genetic comparisons
of case (susceptible) and control (resistant) animals subjected to
similar pre-exposure conditions. These horses were phenotyped
for their innate resistance and susceptibility to natural WNV
infection. Furthermore, the equine OAS gene cluster is more
similar to the human OAS cluster than any other known cluster in
domesticated mammals.
We report associations of SNPs in the equine OAS1 gene with
susceptibility to West Nile encephalitis. Because of the limited
number of well-characterized horses, Fisher’s Exact tests were used
to identify significant differences in allelic and genotypic
frequencies between case and control populations. Ten of the 18
susceptibility-associated SNPs (p,0.05) were identified within the
regulatory region of equine OAS1. While these data suggest a
potential role for equine OAS1 in innate resistance to WNV
disease, identifying causal mutations is complicated by the highly
variable nature of this region within our case population and the
possibility of as yet unidentified mutations in strong linkage
disequilibrium with those reported here.
Although no difference in susceptibility to WNV infection
between major equine breeds in the United States has been
reported, we investigated the potential for false-positive associa-
tions resulting from the two most frequent breeds of our case
population, Quarterhorse and Thoroughbred. Both breeds,
together representing 50% of the case population, were individ-
ually compared to the control population which is almost entirely
SNP ID Gene Region Allele
Case
Allele
Freq.
Control
Allele Freq.
Case
Quarterhorse
Allele Freq.
Case Quarter-
horse Fisher
Exact 262
Case
Thoroughbred
Allele Freq.
Case
Thoroughbred
Fisher Exact 262
ss104806965 RNASEL 39UTR T 0.67 0.73 0.92 0.3934 0.50 0.2018
doi:10.1371/journal.pone.0010537.t003
Table 3. Cont.
Figure 1. OAS1-Luciferase expression constructs, genotypes and population frequency. Schematic diagram of the OAS1 promoter
constructs expressing the luciferase reporter coding region. The interferon stimulated response element (green) is shown from sequence alignments
between horse and human OAS1 promoters. The previously identified dinucleotide microsatellite (black) is shown with corresponding repeat length.
Deletion constructs EcOAS1D59_A-Luc and EcOAS1D59_B-Luc do not contain the microsatellite repeat and upstream sequence. TagSNPs(*)
ss104806918, ss104806922, ss104806924, ss104806926, ss104806927 and genotypes are shown for each construct. Case and control haplotype
frequencies represented by each clone are also shown.
doi:10.1371/journal.pone.0010537.g001
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Figure 3. Effect of IFN on OAS1-luciferase activity in HepG2 cells. HepG2 cells were transfected with the full-length OAS1 constructs and treated
with 100 or 103 AVU IFN for 6 h or 24 h. A dose-response was observed for all clones, averaged across 4 replicates. Treating cells with 103 AVU IFN did not
result in statistically significant differences in fold induction at either timepoint. However, when cells were treated with 100 AVU IFN, EcOAS1_A-Luc
responded with greater fold induction than the other clones (ANOVA, p,0.001). Pair-wise comparisons of EcOAS1_A-Luc to EcOAS1_B-Luc (p=0.001) and
EcOAS1_C-Luc (p=0.003) resulted in statistically significant differences in fold induction after Bonferroni multiple test correction.
doi:10.1371/journal.pone.0010537.g003
Figure 2. Effect of IFN dose on OAS1-luciferase activity in 2fTGH fibroblast cells. Cells were transfected with full-length clones and treated
with 102, 103 or 104 AVU IFN. Reporter activity was measured 24 hours after treatment in triplicate. All constructs showed a dose-response to IFN.
Statistically significant differences in IFN response occurred when cells were treated with 10,000 AVU IFN (ANOVA, p = 0.026). Pair-wise comparison of
EcOAS1_A-Luc and EcOAS1_C-Luc fold induction was statistically significant after Bonferroni correction (p = 0.0275).
doi:10.1371/journal.pone.0010537.g002
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composed of Thoroughbreds. Promoter polymorphism associa-
tions remained significant for each breed, indicating that the
associations reported here are not artifacts based on skewing from
the major case population breeds.
While the multiple SNP associations of the OAS1 promoter with
WNV susceptibility are likely due to linkage disequilibrium, our
association data also suggest a potential functional mechanism by
which OAS1 expression in response to infection might, in part,
confer resistance to WNV. Five tagSNPs were identified and
genotyped in each promoter construct, with clone EcOAS1_A-
Luc representing 65.6% and 23.3% of control and case population
haplotypes, respectively. Previous studies have shown that
expression of the interferon-inducible murine Oas1b during the
early stages of WNV infection (6–9 h post-infection) greatly
reduced virus production compared to later timepoints [30]. Using
transient transfection reporter assays, we investigated potential
effects of the promoter mutations on interferon responsiveness. A
dose-response was observed for both 2fTGH and HepG2 cells,
two cell lines previously utilized in studies of interferon
responsiveness and/or OAS [25–29]. Furthermore, when HepG2
cells were treated with 100 AVU IFN for 6 h, IFN responsiveness
was greater in the clone with the common control-population
haplotype compared to the others, whose promoter haplotypes
were seen more frequently in the case population. Although the
differences in fold induction are not dramatic, they are statistically
significant and warrant future studies that may help determine
how physiological levels of OAS1 expression affect the host
response to WNV infection.
WNV infects several tissues during the early viremic phase
prior to infection of the central nervous system. As a result, the
polymorphisms in the OAS1 upstream region that are associated
with susceptibility to WNV may have a greater functional
relevance on OAS1 expression in other cell lines than those used
here. Cell type has been shown to have a pronounced effect on
the induction of the p69 isoform of OAS2 by IFNB [31].
Specifically, expression levels of p69 OAS were substantially
higher in lymphoid Daudi cells than in human fibrosarcoma
HT1080 cells, the parental cell line of the 2fTGH cells used in
these studies [31,32]. Alternatively, moderate differences in
OAS1 expression may be more readily detectable by quantitative
measures of OAS1 mRNA in WNV-infected cells from horses
having either susceptible or resistant genotypes, as was shown in
previous studies of WNV-infected mouse embryo fibroblasts
[33]. Such infectivity based assays have the advantages of
relying on endogenous IFN levels and on the endogenous OAS1
promoter. The increased sensitivity of such approaches make
them more capable of measuring subtle differences in OAS1
promoter activity that may be important for inhibiting viral
replication during the initial stage of infection. Unfortunately,
these types of infectivity based assays are not easily implemented
in a retrospective case-control study where cases are selected
after they have been diagnosed with fatal WNV disease.
Therefore, experiments to test the effects of individual OAS1
promoter variants will have to await the establishment of equine
cell lines derived from a variety of tissues that are infected early
in WNV disease progression.
While naturally occurring mutations have demonstrated a
central role for Oas in murine resistance to WNV infection, the
radically different composition of the mammalian OAS gene
clusters make it difficult to extend this conclusion. Our results
demonstrate that OAS1 contributes to naturally occurring WNV
susceptibility in a mammal that a) has a very similar OAS gene
cluster to humans and b) may be more amenable to in vivo
investigations of the OAS1 response to WNV infection.
Methods
DNA extraction and SNP genotyping of equine samples
Genomic DNA was extracted from white blood cells isolated
from whole blood. Control DNA samples were genotyped at each
single nucleotide polymorphism as previously described [21]. Case
samples consisted of frozen or archived formalin-fixed paraffin-
embedded (FFPE) liver, kidney or central nervous (spinal cord or
brain) tissues. DNA was extracted from frozen tissue samples after
Proteinase K (Promega, Madison, Wisconsin) digestion, washed
twice with phenol/chloroform and ethanol precipitated. FFPE
liver and kidney samples were deparaffinized with xylene and
DNA extracted using the RecoverAll Nucleic Acid Extraction Kit
(Ambion, Austin, Texas). FFPE brain and spinal cord samples
were deparaffinized with xylene and DNA extracted in a manner
similar to frozen samples after treatment with 6 mg Proteinase K
for 3 days at 55uC. All FFPE DNA samples were amplified using
the Whole Genome Amplification Kit (Sigma, St. Louis, Missouri)
using,100 ng input DNA without further digestion and amplified
for 25 cycles. Amplification products were purified using either the
GeneElute Purification System (Sigma, St. Louis, Missouri) or the
Qiaquick PCR Purification Kit (Qiagen, Valencia, California).
Amplification products from FFPE DNA resulted in fragmented
template ,500 bp in length (data not shown). FFPE samples were
genotyped by sequencing short PCR products ,200 bp. PCR
primer sequences are available upon request.
Transfection Experiment
Genotyped samples were amplified with Easy-A high fidelity taq
(Stratagene, La Jolla, California) and TA-cloned into pCRII
(Invitrogen, Carlsbad, California). Full-length promoters were
amplified using PCR primers F:CGACGGCCAGCTCGA-
GAACCCACAGAATAAACACCACA and R:CAGCTATGA-
CAAGCTTCTGTCAGCCTCTCTCTCTTACG. Primers F:C-
GACGGCCAGCTCGAGCTTAACCTAGAAACGCGTCTGA
and R:CAGCTATGACAAGCTTCTGTCAGCCTCTCTCTC-
TTACG were used to amplify the 59 deletion constructs. Individual
clones were cultured and verified by sequencing. Each primer pair
contains XhoI and HindIII sites used to directionally clone the
promoter regions into pGL3-Basic (Promega, Madison, Wisconsin).
Final constructs were verified by sequencing (Figure S1).
Human fibrosarcoma 2fTGH cells [32] were maintained in
DMEM-F12 medium (Sigma-Aldrich Corp., St. Louis, MO)
supplemented with penicillin/streptomycin/amphotericin B
(PSA, Invitrogen, Carlsbad, CA) and 5% FBS (Hyclone, Loga-
n,UT). Cells were seeded into 12-well plates, allowed to grow until
monolayers were 67–75% confluent and transiently transfected as
described previously [34]. Briefly, luciferase constructs (500 ng/
well) were co-transfected with an equivalent amount of pEF1-Myc-
His LacZ (500 ng/well; Invitrogen) and GenePorter Transfection
Reagent (Gene Therapy Systems, San Diego, CA) according to the
manufacturer’s instructions. Transfected cells were grown over-
night (14–16 h) in medium containing 10% FBS before treatment.
Recombinant ovine interferon tau (IFNT; 108 antiviral units/mg),
a Type I IFN, was produced and assayed as described previously
[35]. Transfected cells were treated with 102 to 104 antiviral units
(AVU) IFNT/mL or left untreated in serum-free medium. Cells
were lysed in Cell Culture Lysis Reagent (Promega, Madison, WI),
and luciferase activity (RLU) was assayed according to the
manufacturer’s instructions (Promega). Human hepatocarcinoma
HepG2 cells were grown in DMEM/PSA/10% FBS to 85%
confluency before transfection as above except that Lipofectamine
2000 (Invitrogen, Carlsbad, CA) was used at a ratio of 1:2.5
(DNA:transfection reagent). HepG2 cells were maintained in
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complete medium during transfection and subsequent treatment
periods.
Statistical Analysis
Statistical association analyses were conducted using STATA 9
[23] software and the R Statistical Environment [36]. Allelic
associations were conducted using Fisher’s Exact tests on 262
tables. Fisher’s Exact tests were conducted on 263 tables to
identify genotypic associations. Significance is reported with
a= 0.05. Haplotype associations were computed using a 262
design by comparing single haplotypes to all others. Case-control
haplotype frequency analysis was also conducted using Phase v2.
Supporting Information
Figure S1 Local alignment of human and horse OAS1
promoters. ClustalX alignment of human (1,036 bp) and equine
(1,091 bp) OAS1 promoters and 59UTR. Equine OAS1 was
sequenced from CHORI BAC 100:I10 as previously described
[21]. Identical sequences are designated with a star (*). The
previously identified human interferon-stimulated regulatory
element (ISRE) is double-underlined [24]. Significantly associated
SNPs are outlined in blue with tagSNPs outlined in red.
Found at: doi:10.1371/journal.pone.0010537.s001 (0.02 MB
DOC)
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